Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

(2011) N Knijn et al.   BRITISH JOURNAL OF CANCER

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

(2011) Jin Hyun Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer

(2011) Toshiaki Watanabe et al.   DISEASES OF THE COLON & RECTUM

Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis

(2011) Fausto Petrelli et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

(2010) Antoine Italiano et al.   ANNALS OF SURGICAL ONCOLOGY

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

PTEN status in advanced colorectal cancer treated with cetuximab

(2009) F V Negri et al.   BRITISH JOURNAL OF CANCER

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

(2009) F Molinari et al.   BRITISH JOURNAL OF CANCER

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

(2009) Jolien Tol et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

(2009) Paloma Cejas et al.   PLoS One

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

(2008) F Cappuzzo et al.   BRITISH JOURNAL OF CANCER

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

(2008) M.-C. Etienne-Grimaldi et al.   CLINICAL CANCER RESEARCH

Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer

(2008) Salvatore Artale et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations and Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases

(2008) Sérgia Velho et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

(2008) D. Santini et al.   ONCOLOGIST